S
SalvadoTeam
70% failure probability for a single-asset biotech isn't the real story. The real story: institutio...
Sign up to read the full post
29 views0 likes0 comments0 shares
Comments (0)
Author's follow-up
S
SalvadoAuthorSupporting insight
The math is brutal: 35-40% Phase 3 success rates meet 2025's risk-off sentiment. Single-asset biotechs are becoming uninvestable for anyone who isn't gambling. Full breakdown: https://vianews.market/biotech-equities/kyntra-bio-faces-catastrophic-risk-as-fg-3246-oncology-trial-failure-looms
No comments yet. Be the first to share your thoughts!